ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a report released on Wednesday, Benzinga reports. They currently have a $72.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s price objective would indicate a potential upside of 13.19% from the stock’s current price.
Other analysts have also issued reports about the company. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Thursday, August 10th. StockNews.com started coverage on ANI Pharmaceuticals in a report on Thursday, August 17th. They set a “hold” rating on the stock. HC Wainwright upped their target price on ANI Pharmaceuticals from $60.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, August 22nd. Finally, Truist Financial reiterated a “buy” rating and set a $70.00 target price on shares of ANI Pharmaceuticals in a report on Monday, August 21st. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $71.67.
ANI Pharmaceuticals Stock Up 1.3 %
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.64. The firm had revenue of $116.50 million during the quarter, compared to analysts’ expectations of $99.87 million. ANI Pharmaceuticals had a positive return on equity of 15.77% and a negative net margin of 1.29%. The company’s revenue was up 57.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) earnings per share. As a group, equities analysts expect that ANI Pharmaceuticals will post 3.2 earnings per share for the current year.
Insider Buying and Selling at ANI Pharmaceuticals
In related news, major shareholder Meridian Venture Partners Ii L sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $58.50, for a total transaction of $11,700,000.00. Following the sale, the insider now owns 1,819,259 shares of the company’s stock, valued at $106,426,651.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Muthusamy Shanmugam sold 14,657 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $51.93, for a total value of $761,138.01. Following the completion of the sale, the chief operating officer now directly owns 32,750 shares in the company, valued at approximately $1,700,707.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Meridian Venture Partners Ii L sold 200,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $58.50, for a total value of $11,700,000.00. Following the transaction, the insider now owns 1,819,259 shares of the company’s stock, valued at approximately $106,426,651.50. The disclosure for this sale can be found here. Insiders have sold 485,190 shares of company stock worth $27,899,445 over the last 90 days. Company insiders own 28.50% of the company’s stock.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of ANI Pharmaceuticals by 9.9% during the second quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock valued at $114,825,000 after acquiring an additional 191,402 shares during the last quarter. Rubric Capital Management LP raised its stake in ANI Pharmaceuticals by 30.7% in the second quarter. Rubric Capital Management LP now owns 847,011 shares of the specialty pharmaceutical company’s stock worth $45,595,000 after buying an additional 198,970 shares in the last quarter. Vanguard Group Inc. raised its stake in ANI Pharmaceuticals by 8.2% in the first quarter. Vanguard Group Inc. now owns 775,299 shares of the specialty pharmaceutical company’s stock worth $21,793,000 after buying an additional 58,523 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in ANI Pharmaceuticals by 2.4% in the second quarter. Dimensional Fund Advisors LP now owns 543,942 shares of the specialty pharmaceutical company’s stock worth $29,280,000 after buying an additional 12,750 shares in the last quarter. Finally, William Blair Investment Management LLC raised its stake in ANI Pharmaceuticals by 1.9% in the second quarter. William Blair Investment Management LLC now owns 539,128 shares of the specialty pharmaceutical company’s stock worth $29,021,000 after buying an additional 9,998 shares in the last quarter. Institutional investors own 69.78% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products.
- Five stocks we like better than ANI Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Shutterstock is the Value Stock they don’t want you to know about
- Insider Trading – What You Need to Know
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.